This Pharmaceutical Issuer's Profit Surges 113%, Turns Out Due to These Sales
Jakarta, CNBC Indonesia - Pharmaceutical issuer PT Phapros Tbk (PEHA) recorded a significant net profit growth of 112.86% in the first quarter of 2026. Phapros’s profitability in Q1/2026 was supported by a 10.17% increase in sales to Rp221.09 billion, compared to Rp200.67 billion in the same period of 2025.
On the other hand, the cost of goods sold (COGS) in the first quarter of 2026 only rose by 5.04%, lower than the sales growth. As a result, the company’s gross profit increased by 16.59% to Rp103.96 billion, compared to Rp89.17 billion in Q1/2025.
In addition to maintaining COGS stability, Phapros’s operating expenses from January to March 2026 were relatively stable, rising only 7.35% year-on-year. The significant sales growth and the ability to keep COGS and operating expenses stable enabled Phapros to achieve a net profit of Rp761.49 million in Q1/2026, a 112.86% increase from the same period the previous year, which had recorded a loss of Rp5.92 billion.
The company’s cash flow as of 31 March 2026 was positive at Rp37.2 billion, up 289% from the position as of 31 March 2025, which was negative at Rp19.6 billion. The cash balance at the end of the period also increased by 165% compared to the end of March 2025.
Acting President Director of PT Phapros Tbk, Ida Rahmi Kurniasih, stated that amid global dynamics full of uncertainties, Phapros has managed to maintain good financial performance, successfully achieving a net profit.
“Various strategic steps have successfully maintained sustainable profitability. After successfully turning the condition from a loss in 2024 to a profit in 2025, we continue to strive to maintain the company’s profitability. This is reflected in the Q1/2026 financial performance with net profit growth reaching 113%. In response to the geopolitical impacts causing rises in material prices and costs, we have already carried out risk mitigation through purchase contracts from the beginning of the year and continue to monitor developments to remain adaptive. The aim is to secure the sales, cost, and net profit targets until the end of the year in line with the RKAP,” said Ida on Friday (24/4/2026).
Branded generic drugs (OGB) became one of the supports for sales growth in January-March 2026. OGB sales in Q1/2026 surged 59% to Rp128.70 billion, compared to Rp80.88 billion in the same period last year. The contribution from adult and child anti-tuberculosis drugs as well as blood booster tablets, which are important government programmes related to TB, anaemia, and stunting, represents PEHA’s commitment to improving the health of the Indonesian people.